MedWatch

Genmab initiates phase III trial with drug against cervical cancer

Positive phase II results prompt Genmab and its collaborative partner Seattle Genetics to submit a US registration application for accelerated approval, which is given to drugs that accommodate an unmet need for the treatment of serious illnesses.

Photo: Joost Melis / Genmab / PR

The biotech firm Genmab will be initiating a phase III trial program with Tisotumab Vedotin for the treatment of cervical cancer with the aim of assessing its efficiency compared with chemotherapy for patients with recurrent or metastatic cervical cancer, according to a Genmab statement on Monday evening.

The InnovaTV 301 trial program is a global randomized phase III study where Tisotumab Vedotin will be compared with the physician's choice of a single-agent chemotherapy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs